EP08.02-064 ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)

Zhou, Q.; Zhang, H.-L.; Jiang, L.-Y.; Shi, Y.-K.; Chen, Y.; Yu, J.-M.; Zhou, C.-C.; He, Y.; Hu, Yongkun; Liang, Zhuoping; Pan, Yonggui; Zhuo, W.-L.; Song, Y.; Wu, G.; Chen, G.-Y.; Lu, Y.; Zhang, C.-Y.; Zhang, Y.-P.; Chen, Y.; Lu, S.; Wu, Y.-L.

doi:10.1016/j.jtho.2022.07.746

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction2

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the final analysis of the ASTRIS China subgroup was announced at the 2022 World Lung Cancer Congress (WCLC). 18 The result showed that osimertinib could obtain PFS benefit after the resistance of first‐line EGFR‐TKIs in a real‐world Chinese population. The ASTRIS study further confirmed the results of AURA3 and consolidated the status of standard treatment in patients with secondary T790M mutation.…”

Section: Introductionmentioning

confidence: 98%

“…After a median follow‐up of 10.2 months, the 1‐year PFS rate was 78.8%. In addition, the final analysis of the ASTRIS China subgroup was announced at the 2022 World Lung Cancer Congress (WCLC) 18 . The result showed that osimertinib could obtain PFS benefit after the resistance of first‐line EGFR‐TKIs in a real‐world Chinese population.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation